Inventor · disambiguated record
Iok-Hou Pang
Also filed as: PANG IOK-HOU
19 granted patents·32 pending applications·169 citations·filing 1995–2019
94Inventor score
Top patents by PatentIndex Score
51 records- 0196US7625927B2Method of treating glaucomaALCON RES LTD·Filed 2007·Granted Dec 1, 2009·52 cites·9 claims
- 0289US7838507B2RNAi inhibition of CTGF for treatment of ocular disordersALCON INC·Filed 2009·Granted Nov 23, 2010·13 cites·7 claims
- 0387US9187525B2Methods of treating ophthalmic diseases using NPR-B agonistsSHIRE ORPHAN THERAPIES GMBH·Filed 2013·Granted Nov 17, 2015·4 cites·20 claims
- 0487US7622454B2RNAi inhibition of CTGF for treatment of ocular disordersALCON INC·Filed 2005·Granted Nov 24, 2009·10 cites·10 claims
- 0585US6444676B1Use of PARP inhibitors in the treatment of glaucomaFiled 2000·Granted Sep 3, 2002·16 cites·4 claims
- 0682US7598288B2Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucomaALCON INC·Filed 2002·Granted Oct 6, 2009·17 cites·19 claims
- 0780US8551938B2NPR-B agonistsHELLBERG MARK R·Filed 2010·Granted Oct 8, 2013·5 cites·1 claims
- 0878US7351407B2Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathiesALCON INC·Filed 2003·Granted Apr 1, 2008·13 cites·11 claims
- 0970US7803824B2Use of inhibitors of Jun N-terminal kinases to treat glaucomaALCON INC·Filed 2006·Granted Sep 28, 2010·1 cites·3 claims
- 1070US7005446B1Use of AP-1 activators to treat glaucoma and ocular hypertensionALCON MFG LTD·Filed 2000·Granted Feb 28, 2006·2 cites·3 claims
- 1169US7384926B2Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucomaALCON INC·Filed 2007·Granted Jun 10, 2008·0 cites·3 claims
- 1266US2007142376A1Control of intraocular pressure using alk5 modulation agentsALCON INC·Filed 2006·Application pending·0 cites
- 1363US2018094029A1Methods of treating ophthalmic diseases using npr-b agonistsSHIRE ORPHAN THERAPIES GMBH·Filed 2017·Application pending·0 cites
- 1461US5681854AUse of aliphatic carboxylic acid derivatives in ophthalmic disordersALCON LAB INC·Filed 1995·Granted Oct 28, 1997·23 cites·12 claims
- 1558US9822147B2Methods of treating ophthalmic diseases using NPR-B agonistsSHIRE ORPHAN THERAPIES GMBH·Filed 2015·Granted Nov 21, 2017·0 cites·10 claims
- 1658US2009312390A1Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucomaALCON INC·Filed 2009·Application pending·0 cites
- 1758US2012115870A1Control of intraocular pressure using alk5 modulation agentsFLEENOR DEBRA L·Filed 2012·Application pending·0 cites
- 1858US2011160210A1Control of intraocular pressure using alk5 modulation agentsALCON INC·Filed 2011·Application pending·0 cites
- 1958US2006142379A1Use of AP-1 activators to treat glaucoma and ocular hypertensionSHADE DEBRA L·Filed 2006·Application pending·0 cites
- 2058US2005203121A1Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseasesFiled 2005·Application pending·0 cites
- 2157US2009202524A1Pai-1 expression and activity inhibitors for the treatment of ocular disordersALCON RES LTD·Filed 2009·Application pending·0 cites
- 2256US7488723B2Use of non-feminizing estrogens as treatment for retinal vascular diseasesALCON INC·Filed 2002·Granted Feb 10, 2009·0 cites·3 claims
- 2356US2004214806A1Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucomaFiled 2002·Application pending·0 cites
- 2456US2008176964A1Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathiesALCON RES LTD·Filed 2008·Application pending·0 cites
- 2555US2004162315A1Use of compounds for treating conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries or traumaFiled 2004·Application pending·0 cites
- 2653US2008107644A1Pai-1 binding modulators for the treatment of ocular disordersALCON MFG LTD·Filed 2007·Application pending·0 cites
- 2752US2011028534A1RNAi INHIBITION OF CTGF FOR TREATMENT OF OCULAR DISORDERSALCON INC·Filed 2010·Application pending·0 cites
- 2852US2006083774A1Neurophilin ligands for treating ocular conditionsALCON INC·Filed 2005·Application pending·0 cites
- 2951US2008025973A1Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disordersALCON MFG LTD·Filed 2007·Application pending·0 cites
- 3051US2006094753A1Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseasesALCON INC·Filed 2005·Application pending·0 cites
- 3149US6303579B1Use of calpain inhibitors to treat ocular neural pathologyALCON LAB INC·Filed 1997·Granted Oct 16, 2001·11 cites·7 claims
- 3248US2021260091A1Use of salidroside and derivative thereof in preparation of inhibitor medicament for diseases of ophthalmic fibrosis caused by abnormalities of extracellular matrix proteinsSHANGHAI NINTH PEOPLES HOSPITAL SHANGHAIJIAOTONG UNIV SCHOOL OF MEDICINE·Filed 2019·Application pending·0 cites
- 3347US2005239871A1Statins for the treatment of ocular hypertension and glaucomaALCON INC·Filed 2005·Application pending·0 cites
- 3446US2012004274A1Use of inhibitors of jun n-terminal kinases to treat glaucomaFLEENOR DEBRA L·Filed 2011·Application pending·0 cites
- 3546US2005137146A1Agents for treatment of glaucomatous retinopathy and optic neuropathyALCON INC·Filed 2004·Application pending·0 cites
- 3645US2011092523A1Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathiesALCON RES LTD·Filed 2010·Application pending·0 cites
- 3745US2008153903A1Inhibitors of protein kinase c-delta for the treatment of glaucomaALCON MFG LTD·Filed 2007·Application pending·0 cites
- 3845US2010311716A1Use of inhibitors of jun n-terminal kinases to treat glaucomaALCON INC·Filed 2010·Application pending·0 cites
- 3944US2010280089A1Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseasesALCON INC·Filed 2010·Application pending·0 cites
- 4043US2011105574A1Pai-1 expression and activity inhibitors for the treatment of ocular disordersALCON RES LTD·Filed 2011·Application pending·0 cites
- 4142US2011098314A1Statins for the treatment of ocular hypertension and glaucomaALCON INC·Filed 2010·Application pending·0 cites
- 4242US2017165200A1Composition of lipid-based nanoparticles for small molecules and macromoleculesUNIV OF NORTH TEXAS HEALTH SCIENCE CENTER·Filed 2016·Application pending·0 cites
- 4342US2004110776A1Use of propentofylline to control intraocular pressureFiled 2002·Application pending·0 cites
- 4441US2010260784A1Pai-1 binding modulators for the treatment of ocular disordersALCON RES LTD·Filed 2010·Application pending·0 cites
- 4539US8252793B2Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucomaCOMBRINK KEITH D·Filed 2011·Granted Aug 28, 2012·0 cites·7 claims
- 4639US2012283260A1Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucomaCOMBRINK KEITH D·Filed 2012·Application pending·0 cites
- 4739US2010183629A1Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disordersALCON RES LTD·Filed 2010·Application pending·0 cites
- 4837US2011144127A1Agents for treatment of glaucomatous retinopathy and optic neuropathyALCON INC·Filed 2011·Application pending·0 cites
- 4936US6906077B1Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseasesALCON MFG LTD·Filed 1999·Granted Jun 14, 2005·2 cites·9 claims
- 5030US6399058B1Methods for treating ocular diseasesALCON MFG LTD·Filed 1998·Granted Jun 4, 2002·0 cites·2 claims
Showing the top 50 of 51 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →